Sjogrens syndrome market

Sjogren’s Syndrome Market, by Drug (Antimalarial Quinolines, Cholinergic Agonists, Corticosteroids and Others (Pain Relief Medication and late phase drug)), by type (Primary and Secondary), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Sep 2022
CMI5210
165 Pages
Excel & Pdf
Pharmaceutical

Summary

For the treatment of Sjorgens’s Syndrome, sometime people manage the treatment using through OTC drug, counter eye drop and but for serious issue prescription drug or surgical procedure is needed.

People with Sjogren’s develop more severe inflammation, involving organs such as the kidneys, lungs, intestines, or brain. For these people, physician may prescribe more aggressive medications such as Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.

The global Sjogren’s syndrome market is estimated to be valued at US$ 234.6 million in 2022 and expected to exhibit a CAGR of 3.5% over the forecast period (2022-2030).

Figure 1. Global Sjogren’s syndrome Market Share (%) in Terms of Value, by Region, 2022

Increasing robust pipeline of drug is expected to aid in the growth of the global Sjogren’s syndrome market.

Increasing robust pipeline of drug is expected to aid in the growth of the global Sjogren’s syndrome market. For instance, according to data published in July 2022, on Nation Institute of Medicine (NIH),states that a randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study is going on to assess the efficacy and safety of the drug Ianalumab in patients with Sjogren's syndrome and the estimated study completion date is in March 2026.

Sjogren’s Syndrome Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 234.6 Mn
Historical Data for:	2017 to 2021	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	3.5%	2030 Value Projection:	US$ 308.4 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug: Antimalarial Quinolines, Cholinergic Agonists, Corticosteroids, Others (Pain Relief Medication and late phase drug) By Type: Primary, Secondary By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Companies covered:	ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis, MorphoSys, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc.
Growth Drivers:	Increasing robust pipeline of drug for the treatment of sjogren’s syndrome Increasing research and development of drug for the treatment of sjogren’s syndrome
Restraints & Challenges:	Treatments currently available either only treat the symptoms or are viewed as ineffective by many patients

Figure 2. Global Sjogren’s syndrome Market Share (%), by Drug, 2022

Global Sjogren’s syndrome Market: Restraint

Many of the Sjogren’s treatments that are currently available either only treat the symptoms or are viewed as ineffective by many patients. For instance, according to data published in September 2021, on Frontiers Media Journal, in a randomized trial, hydroxychloroquine (HCQ) did not significantly reduce the symptoms of primary Sjogren’s after 24 weeks of treatment when compared to placebo. In a similar other studies came to the same conclusion that hydroxychloroquine (HCQ) is not a successful treatment for primary Sjorgens.

Key Players

Major players operating in the global Sjogren’s syndrome market include ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis/MorphoSys, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc.

Table of Content

Table of Contents

*Browse 35 market data tables and 31 figures on "Global Sjogren’s syndrome Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global Sjogren’s syndrome market during the forecast period (2022-2030)?

The global Sjogren’s syndrome market size is estimated to be valued at US$ 234.6 million in 2022 and expected to exhibit a CAGR of 3.5% between 2022 and 2030.

What are the major factors driving the market growth?

Increasing robust pipeline of drug is expected to aid in the growth of the market.

Which is the leading drug segment in the market?

Antimalarial Quinolones drug segment is expected to hold the major market share in the market.

Which region holds the largest market share in the market?

North America holds the largest market share in the market.

What are the key factors hampering the growth of the market?

Many of the Sjogren’s treatments that are currently available either only treat the symptoms or are viewed as ineffective by many patients are the Major factors hampering the market growth.

Which are the major players operating in the market?

Major players operating in the market include ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis/MorphoSys, RemeGen, Resolve Therapeutics, Tear Solutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc.